Najib Ben Khaled

机构：Munich University of Applied Sciences, German Cancer Research Center, LMU Klinikum, Centre de Coopération Universitaire Franco-Bavarois, Comprehensive Cancer Center Erlangen, Molecular Oncology (United States), Deutsches Konsortium für Translationale Krebsforschung, Technical University of Munich, Ludwig-Maximilians-Universität München · ORCID：0000-0002-9681-2542

发表论文 113 篇 · 总被引 922 次 · h-index 18

代表论文

• Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity (2025 · JHEP Reports · 被引 6)
• Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study (2025 · Therapeutic Advances in Medical Oncology · 被引 4)
• Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance (2025 · Cellular Oncology · 被引 4)
• Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis (2025 · Journal of Hepatocellular Carcinoma · 被引 3)
• ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC). (2026 · Journal of Clinical Oncology · 被引 2)
• Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study (2025 · JHEP Reports · 被引 2)